Today, we proudly presented preclinical data for our lead program at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA. This development highlights the dose-dependent survival advantage of AUTX-703 in a patient-derived AML model. These findings validate the strength of our AURIGIN? platform, which combines AI and machine learning to identify innovative oncology targets. With IND submissions on track before year-end and plans to move into the clinic in 2025, we’re excited to bring next-generation cancer therapies closer to reality. ?? Read the full press release here: https://lnkd.in/eFgXfNtC #ASH
Auron Therapeutics, Inc.的动态
最相关的动态
-
This week, we were excited to attend and present at the #2024AACR Annual Meeting. Our data scientist Jianli Zhou shared some of the innovative work on our drug candidate LP-284, currently in Phase 1 #clinicaltrial for Non-Hodgkin's lymphomas (#NHL) and solid tumors, and were able to connect with the #CancerResearch community. Leveraging #ArtificialIntelligence, #MachineLearning, and #genomics, Lantern Pharma Inc. (Nasdaq: LTRN) is working towards transforming the cost, pace, and timeline of oncology drug discovery and development. Check out the poster on our website! https://lnkd.in/e_j4azc9 #oncology #drugdiscovery #drugdevelopment #oncologyresearch #AI #Genomics #ML #Datascience #24AACR #AACR2024 American Association for Cancer Research
-
Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.
Implementation of an FDA-cleared tumor profiling assay to enable localized Precision Oncology testing for patients
learn-more.com
-
Central Laboratory Services | Non-Clinical | Clinical Phase I-IV | Preclinical | Early Development | Business Development | Inside Sales
Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.
Implementation of an FDA-cleared tumor profiling assay to enable localized Precision Oncology testing for patients
share.postbeyond.com
-
Caris Life Sciences Announces a Strategic Collaboration with Ontada? to Advance Oncology Research and the Adoption of Precision Medicine https://lnkd.in/ggFCYphh The collaboration brings together Caris’ extensive genomic data and molecular expertise with Ontada’s robust clinical data and research capabilities to drive next-gen therapeutic development and advance cancer care IRVING, Texas, Jan. 16, 2025 /PRNewswire/ — [...]
Caris Life Sciences Announces a Strategic Collaboration with Ontada? to Advance Oncology Research and the Adoption of Precision Medicine
https://txbn.org
-
Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.
Implementation of an FDA-cleared tumor profiling assay to enable localized Precision Oncology testing for patients
learn-more.com
-
Innovations in Cancer Diagnostics to be revealed during ASCO 2024. With the arrival of the 2024 American Society of Clinical Oncology Annual Meeting, excitement mounts for the forthcoming data unveilings by top players in oncology diagnostics. Key industry leaders like Predicine, Natera, Guardant Health, Precede Biosciences, GRAIL, Exact Sciences, 燃石医学 Burning Rock Biotech, SAGA Diagnostics, HaploX Biotechnology, Personalis, Inc., Foresight, Illumina, and others are poised to present their latest clinical study findings. These presentations are poised to spotlight notable advancements and breakthroughs in cancer diagnostics, heralding a new era in the battle against cancer. Get detailed insights: https://lnkd.in/gwcB4m6m #ASCO2024 #OncologyDiagnostics #CancerResearch #ClinicalStudy #Predicine #Natera #GuardantHealth #MedicalInnovations #CancerDetection #DataPresentations #CancerInnovations #FightAgainstCancer
Innovations in Cancer Diagnostics | ASCO 2024
delveinsight.com
-
Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.
Implementation of an FDA-cleared tumor profiling assay to enable localized Precision Oncology testing for patients
learn-more.com
-
Discover the buzz from #ASCO24! ? Our latest analysis dives deep into the 42K+ tweets from this year's ASCO Annual Meeting, showcasing the buzzing conversations around monoclonal antibodies, drug targets, and small molecules. With over 230M impressions and 2M engagements, ASCO's digital engagement is at an all-time high. ?????? ????????????????????: - 86% of tweets from individual oncologists or industry professionals - Top trending cancer topics: Lung, Breast, and Hematologic Cancer Explore the insights and see how conversations are shaping the future of oncology. Check out our flyer to see the detailed breakdown and trending topics that captivated the ASCO audience. #Oncology #ASCO2024 #CancerResearch #ProcDNAInsights #MedicalData #ProcDNA
-
In business news, BeiGene has proposed a name change to BeOne Medicines. The new logo is clever. As per their explanation: The word “Onc” spelled in red within “One” illustrates our redoubled commitment to oncology; and The power button within the last “e” represents our always “on” approach in pursuing novel medicines that turn cancer “off” by disrupting key drivers of cancer cell growth and survival, harnessing the body’s immune system to attack tumors, and targeting specific biomarkers of cancer. The tilted angle of the button embodies our path which is not always straight-forward as we push the boundaries of science. https://lnkd.in/eDsUDdXy
-
-
We are seeking insights on key metrics in functional precision oncology, focusing on in vitro tumor sensitivity assays. If you're working in clinical research or are a CRO or a commercial lab, your input is invaluable.????Take the survey here:?https://lnkd.in/ehpyGYf9 Help us advance oncology research and treatment! #Oncology #PrecisionMedicine #CancerResearch #Survey
Functional precision oncology survey
docs.google.com
Trailblazing Data Maestro: Engineering New Frontiers in Analytics
2 个月Congratulations on this remarkable achievement, as your groundbreaking work not only showcases the potential of AUTX-703 but also positions you at the forefront of innovation in cancer treatment!